Answers are grounded in this paper and cite their sources.
Proposes a new model explaining cancer prevention outcomes via gene-diet interactions and baseline states.
Three bodies of evidence about cancer prevention are usually told as three separate disappointments. Micronutrient-supplement trials appear not to replicate — folate, selenium, β-carotene, vitamin E and others protect in some populations and do nothing, or cause harm, in others. Gene–diet-interaction studies accumulate as a case-by-case catalogue with no general rule. And neurodevelopmental risk genes turn out to be cancer genes, yet people with autism carry more variation in cancer-driver genes while developing less clinical cancer. This paper proposes that these are not three failures but one signature. If carcinogenesis is treated as a commit-with-hysteresis race — a competition between genome-maintenance / differentiation and damage / proliferation that, once committed, is expensive to reverse — then a single order parameter, the tissue's baseline trace-state, organises all three. An input (a supplement, or the loss of a brake gene) tilts the race toward repair when baseline trace is low and toward the already-committed clone when baseline trace is high; the same input therefore protects some and harms others. The low-trace-protect / high-trace-harm signature is shown to recur across nine of fifteen surveyed, chemically unrelated supplement–cancer systems, with two informative non-fits that bound it to inputs feeding a rate-limiting route in an active trace-accumulating process. Alcohol behaves as a negative cofactor with the mirror signature, offering a testable resolution of the discordance between alcohol's observational and genetic-causal effects on breast cancer. The gene route and the cofactor route are not competitors: a risk gene shifts the commit-landscape but does not determine the commit, which is gated by the cofactor environment. The biology is borrowed and heavily studied, and the closest existing readings — hormesis and the “supplement the deficient, not the replete” baseline-status account — already cover part of the ground. What the organising lens adds beyond them, and what the paper stakes itself on, are two discriminating, currently-untested predictions: that the post-bottleneck active form of a cofactor widens its cancer-safe window, and that the cancer outcome of a neurodevelopmental risk gene is a directional function of the cofactor landscape. Both are stated with their falsifiers and the individual-level tests that would decide them. Series position. A paper in the Friction Theory series; the commit-with-hysteresis, route-competition substrate is developed in the series' foundational papers, and the preventive cofactor-support and compound-race-pathology material is developed in the clinical companions.
No takes yet. Share an insight, caveat, or question.
Tomas Pødenphant Lund (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: